Drug intelligence / Profile preview

MBI-401

Development stage: Unknown
Lead developer: Matrix Biomed
Modality: Small Molecules

Overview

MBI-401 is a Tempol-based small molecule developed by Matrix Biomed. It is designed to modulate the activity of Hypoxia-Inducible Factor 1 (HIF-1) and Hypoxia-Inducible Factor 2 (HIF-2), which are master transcription factors responsible for the cellular response to hypoxia and are heavily involved in cancer progression and treatment-related side effects. MBI-401 is specifically being investigated for its ability to mitigate toxicities associated with chemotherapy, with a primary focus on cisplatin-induced toxicities. By modulating the HIF pathway, the drug aims to protect healthy tissues from the damaging effects of cytotoxic agents. It is currently in Phase 2 clinical development.

Targets

EPAS1 (Hypoxia-inducible factor 2-alpha)HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on MBI-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MBI-401.

Explore the full profile